<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41012540</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1205</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics17091205</ELocationID><Abstract><AbstractText><b>Background:</b> The efficacy of a single oral dose of Ivermectin as prophylaxis for SARS-CoV-2 is uncertain. This trial sought to evaluate the effectiveness of a single oral low dose of Ivermectin to prevent SARS-CoV-2 infection or reduce symptoms if infection did occur. <b>Methods:</b> Asymptomatic community-dwelling adults were enrolled in this study within 72 h of close contact with a case of SARS-CoV-2. Participants were randomised, stratified by vaccination status and exposure site, to a single oral 200 &#xb5;g/kg dose of Ivermectin or placebo. The primary outcome was conversion to a positive polymerase chain reaction (PCR) or rapid antigen test (RAT) for SARS-CoV-2 within 14 days of close contact. Secondary outcomes were restricted to those who met the primary outcome. They included the following: days alive free of symptoms in the 14 (DAFS1-14) and 28 (DAFS1-28) days following intervention and days from close contact until a positive PCR or RAT for SARS-CoV-2. <b>Results:</b> A total of 536 participants registered for this trial. Of these, 86 met inclusion criteria and were randomised. 68 adhered to the trial protocol and were included in the analysis. A total of 11/36 (Ivermectin arm) and 11/32 (placebo arm) met the primary outcome. After controlling for age and prior SARS-CoV-2 infection, the estimate (95% confidence interval (95% CI)) of the effect of Ivermectin (compared to placebo) on the absolute value of the proportion of participants converting to a positive PCR or RAT was -0.051 (-0.26 to 0.16), <i>p</i> = 0.63. After controlling for prior SARS-CoV-2 infection, age, body mass index, hypertension and lung disease, the average treatment effect (Ivermectin versus placebo) on DAFS1-14 was 2.5 days (95%CI 1.1 to 4.5), <i>p</i> = 0.036, and for DAFS1-28, was 2.3 days (95% CI 0.7 to 3.3), <i>p</i> = 0.35. The mean (standard deviation) number of days from close contact until a positive PCR or RAT was 5.0 (4.1) days for the Ivermectin group versus 2.6 (0.8) days for the placebo group. After controlling for age and prior SARS-CoV-2 infection, the average treatment effect (95%CI), Ivermectin versus placebo, on days from close contact until a positive PCR or RAT was 2.3 days (95% CI 1.1 to 3.4), <i>p</i> = 0.033. <b>Conclusions:</b> We did not demonstrate that a single oral low dose of Ivermectin administered to asymptomatic adults within 72 h of close contact with a case of SARS-CoV-2 prevents conversion to a positive PCR or RAT. However, the trial had a small sample size and does not exclude a clinically meaningful effect of Ivermectin on conversion to a positive PCR or RAT. Amongst those who did convert to a positive PCR or RAT, the use of Ivermectin significantly lengthened the time from close contact to conversion and increased the number of days alive free of symptoms following intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wagstaff</LastName><ForeName>Kylie M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Knox Private Hospital, Wantirna, VIC 3152, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Holmesglen Private Hospital, Moorabbin, VIC 3189, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herschtal</LastName><ForeName>Alan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0004-2061-4787</Identifier><AffiliationInfo><Affiliation>School of Public Health and Preventative Medicine, Monash University, Melbourne, VIC 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajter</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Pulmonary and Sleep Consultants, 1001 South Andrews Ave, Fort Lauderdale, FL 33316, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajter</LastName><ForeName>Juliana Cepelowicz</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Pulmonary and Sleep Consultants, 1001 South Andrews Ave, Fort Lauderdale, FL 33316, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallaberger</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Trials Australia, 30 Royal Parade, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smileski</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Trials Australia, 30 Royal Parade, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanagalingam</LastName><ForeName>Amala</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Trials Australia, 30 Royal Parade, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jans</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-5115-4745</Identifier><AffiliationInfo><Affiliation>Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">ivermectin</Keyword><Keyword MajorTopicYN="N">post-exposure prophylaxis</Keyword><Keyword MajorTopicYN="N">randomised controlled trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41012540</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics17091205</ArticleId><ArticleId IdType="pii">pharmaceutics17091205</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>